Orthopedic Devices Panel Rejects Stryker’s OP-1 Putty For Spinal Fusion
This article was originally published in The Gray Sheet
Executive Summary
FDA's Orthopedic and Rehabilitation Devices advisory panel voted 6-1 to recommend against approval of Stryker Biotech's OP-1 Putty spinal fusion product March 31
You may also be interested in...
Olympus Acquires Stryker OP-1 Products, Spawns Biotech Division
Olympus Corp. is forming a new business focused on regenerative medicine product offerings following the Dec. 6 purchase of Stryker Biotech's OP-1 orthopedic bone protein business for $60 million.
Olympus Acquires Stryker OP-1 Products, Spawns Biotech Division
Olympus Corp. is forming a new business focused on regenerative medicine product offerings following the Dec. 6 purchase of Stryker Biotech's OP-1 orthopedic bone protein business for $60 million.
Medicare Advisors Set To Meet On BMPs; AHRQ Tech Assessment Issued
Evidence on the harms and benefits of bone morphogenetic protein orthopedic products will be scrutinized by Medicare advisors this week